Physician profile
Michael E Decherd
NPI 1033163084
$6,679.49
in general payments reported to CMS, 2019-2025
12 companies · $1,040 in 2025
The $1,040 reported for 2025 was more than what a typical Plastic Surgery provider received nationally (typical 2025 total: $380).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $953 · 2020: $164 · 2021: $765 · 2022: $855 · 2023: $1,175 · 2024: $1,727 · 2025: $1,040.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,942.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,942.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,452.24 | 2023-2025 | Botox, Natrelle Saline-Filled Breast Implants |
| Allergan, INC. | $1,787.78 | 2019-2022 | |
| Musculoskeletal Transplant Foundation INC. | $486.19 | 2019-2025 | |
| Tela Bio, INC. | $484.58 | 2022-2024 | Ovitex 2s |
| Revance Therapeutics, INC. | $439.36 | 2024-2025 | Daxxify, Daxi |
| Tepha INC | $262.26 | 2019 | |
| Innovation Technologies INC | $176.19 | 2024 | Irrisept |
| Mentor Worldwide LLC | $166.48 | 2021-2024 | Mentor Memorygel Resterilizable Gel Sizer |
| Davol INC. | $143.01 | 2022 | |
| Acelrx Pharmaceuticals, INC. | $121.13 | 2019 | |
| Motiva USA, LLC | $95.68 | 2025 | |
| Galderma Laboratories, L.P. | $64.59 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Decherd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.